SLDB Solid Biosciences Inc.

8.81
+2.66  (+43%)
Previous Close 6.15
Open 6.84
Price To Book 4.1
Market Cap 405,271,708
Shares 46,001,329
Volume 2,826,312
Short Ratio
Av. Daily Volume 516,527

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 update due end of 2019.
SGT-001
Duchenne Muscular Dystrophy

Latest News

  1. Here's Why Solid Biosciences Is Soaring Today
  2. Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
  3. Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update
  4. Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
  5. Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
  6. Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
  7. Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
  8. Here’s What Hedge Funds Think About Solid Biosciences Inc. (SLDB)
  9. Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying
  10. Bain's second life sciences fund comes in over $1 billion
  11. Vertex enters Duchenne field with $245M buy of Exonics
  12. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)
  13. This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
  14. Solid Bio’s Plunge Sends a Warning on Gene Therapies
  15. Here's Why Solid Biosciences Fell as Much as 40.9% Today
  16. Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial
  17. The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
  18. Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
  19. Here’s What Hedge Funds Think About About Solid Biosciences Inc. (SLDB)